| Literature DB >> 30709700 |
Elisha M Wachman1, Lindsay A Farrer2.
Abstract
Neonatal abstinence syndrome (NAS) due to in-utero opioid exposure is a growing epidemic with significant variability in clinical presentation and severity. Currently, NAS severity cannot be predicted based on clinical factors alone. To date, small studies have identified genetic variants in opioid receptor and stress response genes that are associated with differences in NAS pharmacologic treatment rates and length of hospitalization. In addition, epigenetic variation in the mu opioid receptor (OPRM1) gene has been associated with differences in NAS hospitalization outcomes. Examination of maternal genetic and epigenetic profiles may assist in prediction of NAS severity. Large-scale genomic studies are needed to elucidate the genetic architecture of and epigenetic modification related to NAS in order to develop more tailored personalized treatments for NAS.Entities:
Keywords: Epigenetics; Genetics; Neonatal Abstinence Syndrome (NAS); Neonatal Opioid Withdrawal Syndrome (NOWS)
Mesh：
Substances：
Year: 2019 PMID： 30709700 DOI： 10.1016/j.siny.2019.01.002
Source DB: PubMed Journal: Semin Fetal Neonatal Med ISSN： 1744-165X Impact factor: 3.926